Summary
Advances in research mean that for many cancers, there are more treatment options than ever. Physicians face a growing number of diagnostic tests, treatments and guidelines, making it increasingly challenging to ensure each patient receives the right treatment.
The aim of OPTIMA is to harness the power of artificial intelligence to advance treatments and facilitate decision-making for physicians and patients with prostate, breast and lung cancer.
At the heart of OPTIMA will be Europe’s first interoperable, large scale oncology data and evidence generation platform with data from over 200 million people. The platform, which will be GDPR (General Data Protection Regulation) compliant, will host data sets, data analysis tools, federated learning tools, and artificial intelligence (AI) tools.
The project will use the platform to drive the generation of new knowledge by developing advanced analytics and AI models to identify, prioritise and fill the main knowledge gaps in prostate, breast and lung cancer, and propose improved clinical guideline recommendations. Finally, they will develop AI-based decision support tools that can help clinicians, together with their patients, make treatment decisions based on the leading clinical practice guidelines.
By designing the platform based on the needs of clinicians and patients, and by including the major guideline offices for prostate, breast and lung cancer, the project is well placed to have an impact care down the line.
Achievements & News
May 2023
Three IMI projects have contributed to UroEvidenceHub, a platform that will provide physicians with personalised healthcare recommendations for patients with...
Participants
Show participants on mapEFPIA companies
- Abbvie Inc, North Chicago, Illinois, United States
- Amgen, Brussels, Belgium
- Astrazeneca AB, Södertälje, Sweden
- Bayer Aktiengesellschaft, Leverkusen, Germany
- F. Hoffmann-La Roche AG, Basel, Switzerland
- Pfizer Limited, Sandwich, Kent , United Kingdom
Universities, research organisations, public bodies, non-profit groups
- Association Eisbm, Vourles, France
- Deutsche Krebsgesellschaft Ev, Berlin, Germany
- Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
- European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium
- European Respiratory Society, Lausanne, Switzerland
- Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina, Barcelona, Spain
- Helmholtz-Zentrum Dresden-Rossendorf Ev, Dresden, Germany
- Institut De Cancerologie De L'Ouest, Angers, France
- Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
- Lunds Universitet, Lund, Sweden
- Queen Mary University Of London, London, United Kingdom
- Region Uppsala, Uppsala, Sweden
- Tartu Ulikool, Tartu, Estonia
- The University Court Of The University Of Aberdeen, Aberdeen, United Kingdom
- Universita Vita-Salute San Raffaele, Milano, Italy
- Universitat Wien, Vienna, Austria
- Universiteit Maastricht, Maastricht, Netherlands
- University College London, London, United Kingdom
- University of Oxford, Oxford, United Kingdom
- Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Arttic Innovation GMBH, Munchen, Germany
- Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain
- Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg
- Istituto Europeo Di Oncologia SRL, Milan, Italy
- Mutabor Technologies GMBH, Hamburg, Germany
- Owkin France, Paris, France
- Smart Reporting GMBH, München, Germany
- Stichting European Urological Foundation, Arnhem, Netherlands
- Ttopstart BV, Bilthoven, Netherlands
- Ydeal.Net Software Lda, Santa Maria da Feira, Portugal
Patient organisations
- European Lung Foundation, Sheffield, United Kingdom
Third parties
- Lungs Europe, Brussels, Belgium
Non EFPIA companies
- Helios Klinikum Emil Von Behring GMBH, Berlin, Germany
Participants | |
---|---|
Name | EU funding in € |
Arttic Innovation GMBH | 162 857 |
Association Eisbm | 884 000 |
Deutsche Krebsgesellschaft Ev | 99 993 |
Erasmus Universitair Medisch Centrum Rotterdam | 575 259 |
European Cancer Patient Coalition (left the project) | 24 843 |
European Lung Foundation | 118 803 |
European Organisation For Research And Treatment Of Cancer Aisbl | 75 001 |
European Respiratory Society | 126 750 |
Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina | 200 416 |
Gmv Soluciones Globales Internet Sau | 744 353 |
Helmholtz-Zentrum Dresden-Rossendorf Ev | 684 000 |
Information Technology For Translational Medicine (Ittm) SA | 787 500 |
Institut De Cancerologie De L'Ouest | 90 000 |
Istituto Europeo Di Oncologia SRL | 50 000 |
Ludwig-Maximilians-Universitaet Muenchen | 40 000 |
Lunds Universitet | 71 000 |
Owkin France | 299 962 |
Queen Mary University Of London | 220 000 |
Region Uppsala | 483 000 |
Smart Reporting GMBH | 398 250 |
Stichting European Urological Foundation | 822 280 |
Tartu Ulikool | 470 000 |
The University Court Of The University Of Aberdeen | 613 424 |
Ttopstart BV | 326 218 |
Universita Vita-Salute San Raffaele | 50 125 |
Universitat Wien | 433 130 |
Universiteit Maastricht | 300 000 |
University College London | 98 590 |
University of Oxford | 967 594 |
Uppsala Universitet | 67 875 |
Ydeal.Net Software Lda | 162 275 |
Third parties | |
Name | Funding in € |
Lungs Europe | 12 500 |
Total Cost | 10 459 998 |